Cryptotanshinone inhibits osteoclast differentiation by targeting LCP1 to suppress diabetic osteoporosis
International Immunopharmacology · 2026-02 · 170 · 116115
DOI: 10.1016/j.intimp.2025.116115 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-02. Verfasst von Mingming Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou 215000, China. Hauptthemen laut MEDLINE: Phenanthrenes, Osteoclasts, Osteoporosis, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
As a frequent complication of diabetes, diabetic osteoporosis (DOP) represents a growing clinical and public health challenge. The increased osteoclastogenesis in diabetic pathological states results in bone resorption and bone loss and the exacerbation of osteoporosis. Cryptotanshinone, a fat-soluble diterpenoid anthraquinone compound extracted from Salvia. miltiorrhiza Bge, has been demonstrated efficacy in the treatment of a variety of diseases. In this study, we present evidence that cryptotanshinone inhibits RANKL-induced osteoclast differentiation in a concentration-dependent manner in vitro. Furthermore, cryptotanshinone suppresses diabetic osteoporosis by inhibiting osteoclastogenesis in vivo. Mechanistically, cryptotanshinone binds to lymphocyte cytosolic protein 1 (LCP1) so that suppressing osteoclast fusion to reduce bone resorption. Collectively, these findings suggest that cryptotanshinone suppresses osteoclast differentiation and bone loss of DOP by targeting LCP1. Consequently, cryptotanshinone may represent a promising therapeutic agent for diabetic osteoporosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou 215000, China.
- Department of Basic Medicine, Dali University, Dali, Yunnan 671000, China.
- Department of Endocrinology and Metabolism, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou 215000, China. Electronic address: fang_ya1993@163.com.
- Department of Endocrinology and Metabolism, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou 215000, China. Electronic address: justin_yesterday@outlook.com.
Förderung
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Li, M., Zhang, Y., Fang, Y., & Chen, S. (2026). Cryptotanshinone inhibits osteoclast differentiation by targeting LCP1 to suppress diabetic osteoporosis. International Immunopharmacology, 170, 116115. https://doi.org/10.1016/j.intimp.2025.116115
Vancouver
Li M, Zhang Y, Fang Y, Chen S. Cryptotanshinone inhibits osteoclast differentiation by targeting LCP1 to suppress diabetic osteoporosis. International Immunopharmacology. 2026;170:116115. doi:10.1016/j.intimp.2025.116115
BibTeX
@article{Li2026,
author = {Li, Mingming and Zhang, Yixin and Fang, Ya and Chen, Siyu},
title = {Cryptotanshinone inhibits osteoclast differentiation by targeting LCP1 to suppress diabetic osteoporosis},
journal = {International Immunopharmacology},
year = {2026},
volume = {170},
pages = {116115},
doi = {10.1016/j.intimp.2025.116115}
}
EUVIMED